LARGE B-CELL LYMPHOMA (LBCL)
Clinical trials for LARGE B-CELL LYMPHOMA (LBCL) explained in plain language.
Never miss a new study
Get alerted when new LARGE B-CELL LYMPHOMA (LBCL) trials appear
Sign up with your email to follow new studies for LARGE B-CELL LYMPHOMA (LBCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
AI takes on lymphoma: personalized drug cocktail aims to outsmart cancer in older patients
Disease control Not yet recruitingThis study tests whether an artificial intelligence (AI) system can help choose the best combination of drugs for older patients newly diagnosed with large B-cell lymphoma. Participants are first treated with a standard two-drug regimen (ZR2), then those at intermediate or high r…
Matched conditions: LARGE B-CELL LYMPHOMA (LBCL)
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
AI takes on lymphoma: personalized treatment strategy under trial
Disease control Not yet recruitingThis study compares an AI-driven treatment strategy to standard therapy (Pola-R-CHP) for people with previously untreated large B-cell lymphoma. About 178 participants will be grouped by risk using an AI model, and those at intermediate or high risk will receive either a personal…
Matched conditions: LARGE B-CELL LYMPHOMA (LBCL)
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New hope: drug may prevent dangerous reactions to cancer immunotherapy
Disease control Not yet recruitingThis study tests whether the drug emapalumab can prevent severe side effects (cytokine release syndrome and nerve-related toxicity) in people with lymphoma or multiple myeloma receiving bispecific antibody therapy. About 60 adults will take emapalumab before their cancer treatmen…
Matched conditions: LARGE B-CELL LYMPHOMA (LBCL)
Phase: PHASE2 • Sponsor: NYU Langone Health • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Experimental CAR-T therapy takes on tough lymphoma
Disease control Not yet recruitingThis early-phase trial is testing a new type of immune cell therapy called CD19X CAR-T for people with large B-cell lymphoma that has come back or not responded to other treatments. Only 3 participants will receive the therapy after a short course of chemotherapy to prepare their…
Matched conditions: LARGE B-CELL LYMPHOMA (LBCL)
Phase: PHASE1, PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New hope for hard-to-treat lymphoma: three-drug combo enters early trials
Disease control Not yet recruitingThis early-phase trial tests whether combining three drugs (golcadomide, poseltinib, and rituximab) can shrink or control tumors in people with relapsed or refractory large B-cell lymphoma. About 20 adults will take part. The goal is to see if the combination works better than cu…
Matched conditions: LARGE B-CELL LYMPHOMA (LBCL)
Phase: PHASE1, PHASE2 • Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC